Executive Summary
Cell MedX Corp (CMXC) reported QQ4 2024 results that reflect a nascent operating profile with no disclosed revenue and a material net loss, underscored by acute liquidity constraints. Operating income was negative at -$116,960 and net income came in at -$124,957 for the quarter, with EPS of -0.003. Depreciation and amortization contributed a non-cash expense of $84,130, while general and administrative expenses dominated quarterly spend at $119,023, with R&D outlays of $2,062. Free cash flow was negative at -$30,259, and net cash provided by operating activities stood at -$30,256, signaling ongoing cash burn despite a modest quarterly capital outlay of $3 for capex.
The balance sheet shows a distressed liquidity position: cash and cash equivalents of $43,415 versus total current liabilities of $872,577, resulting in a current ratio of approximately 0.053. Total liabilities rest at $872,577 against total assets of $46,122, yielding negative stockholders’ equity of about -$826,455. Net debt approximates $244,051, highlighting a delicate run-way that depends on external financing or a meaningful revenue/partnering inflection. The company’s stated market position revolves around the eBalance professional and home systems for wellness and pain management, but the QQ4 2024 results indicate that financial health and near-term profitability are constraining value realization. Management commentary or transcript context is not provided in the data set, limiting clarity on near-term strategic catalysts. Investors should monitor liquidity developments, potential partnerships, or licensing arrangements that could unlock value, as well as any forward-looking guidance disclosed in forthcoming filings or calls.
Key Performance Indicators
QoQ: -197.49% | YoY:-80.57%
QoQ: -204.16% | YoY:-57.41%
QoQ: -203.45% | YoY:-130.77%
Key Insights
Revenue: No quarterly revenue reported for QQ4 2024 (revenue field null). Gross profit: not disclosed. Operating income: -$116,960; YoY: -80.57%; QoQ: -197.49%. Net income: -$124,957; YoY: -57.41%; QoQ: -204.16%. EBITDA: -$116,960; D&A: $84,130; Interest expense: $7,996; Tax expense: not reported. EPS (diluted): -$0.003; Weighted average shares (outstanding): 41,369,668. CFO: -$30,256; Capex: -$3; Free cash flow: -$30,259; Net change in cash: -$36,262; Cash at end of period: $43,415; Cash at...
Financial Highlights
Revenue: No quarterly revenue reported for QQ4 2024 (revenue field null). Gross profit: not disclosed. Operating income: -$116,960; YoY: -80.57%; QoQ: -197.49%. Net income: -$124,957; YoY: -57.41%; QoQ: -204.16%. EBITDA: -$116,960; D&A: $84,130; Interest expense: $7,996; Tax expense: not reported. EPS (diluted): -$0.003; Weighted average shares (outstanding): 41,369,668. CFO: -$30,256; Capex: -$3; Free cash flow: -$30,259; Net change in cash: -$36,262; Cash at end of period: $43,415; Cash at beginning: $79,677. Liquidity: current ratio 0.0529; quick ratio 0.0529; cash ratio 0.0498. Leverage and solvency: total debt $287,466; net debt $244,051; total assets $46,122; total liabilities $872,577; total stockholders’ equity -$826,455. Valuation signals: price-to-book and price-to-earnings are negative or highly unfavorable; enterprise value multiple -18.00; price-to-sales and related metrics are not meaningful in a no-revenue context.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
-116.96K |
-80.57% |
-197.49% |
| Net Income |
-124.96K |
-57.41% |
-204.16% |
| EPS |
0.00 |
-130.77% |
-203.45% |
Key Financial Ratios
operatingCashFlowPerShare
$-0
Management Commentary
No earnings call transcript or management quotes are provided in the data for QQ4 2024. As a result, management commentary and strategic guidance from an earnings call could not be integrated from the supplied dataset.
Forward Guidance
No formal forward guidance is provided in the dataset for QQ4 2024. Given the absence of reported revenue and the pronounced cash burn, near-term guidance would be pivotal to assess the company’s liquidity runway and monetization plan. In a micro-cap healthcare/devices space, catalysts that could meaningfully shift the outlook include: (1) securing one or more revenue-generating partnerships or licensing deals for the eBalance platform; (2) regulatory clearance or expanded clinical adoption that unlocks payer reimbursement; (3) a capital raise or debt facility to extend runway; (4) a material reduction in operating costs or a restructuring that improves gross margin. Until such catalysts are publicly communicated, the risk of a continued cash burn and potential financing needs remains high. Key factors investors should monitor include: any guidance on revenue milestones, runway spelling, and updated liquidity projections tied to corporate actions or collaborations.